115 related articles for article (PubMed ID: 33797637)
1. Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence.
Fukunaga M; Mimori K; Masuda T; Hu Q; Yamada K; Mori M
Surg Today; 2021 Oct; 51(10):1671-1681. PubMed ID: 33797637
[TBL] [Abstract][Full Text] [Related]
2. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer.
De la Fuente López M; Landskron G; Parada D; Dubois-Camacho K; Simian D; Martinez M; Romero D; Roa JC; Chahuán I; Gutiérrez R; Lopez-K F; Alvarez K; Kronberg U; López S; Sanguinetti A; Moreno N; Abedrapo M; González MJ; Quera R; Hermoso-R MA
Tumour Biol; 2018 Nov; 40(11):1010428318810059. PubMed ID: 30419802
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Ootani K; Yasuda K; Murono K; Watanabe T
Oncology; 2017; 92(1):31-38. PubMed ID: 27794579
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.
Volpato M; Perry SL; Marston G; Ingram N; Cockbain AJ; Burghel H; Mann J; Lowes D; Wilson E; Droop A; Randerson-Moor J; Coletta PL; Hull MA
Oncotarget; 2016 May; 7(19):28139-50. PubMed ID: 27058904
[TBL] [Abstract][Full Text] [Related]
5. The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer.
Xu G; Jiang L; Ye C; Qin G; Luo Z; Mo Y; Chen J
Front Immunol; 2021; 12():724429. PubMed ID: 34512652
[TBL] [Abstract][Full Text] [Related]
6. Postoperative changes in plasma miR21-5p as a novel biomarker for colorectal cancer recurrence: A prospective study.
Fukada M; Matsuhashi N; Takahashi T; Sugito N; Heishima K; Yoshida K; Akao Y
Cancer Sci; 2021 Oct; 112(10):4270-4280. PubMed ID: 34270831
[TBL] [Abstract][Full Text] [Related]
7. The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis.
Han SX; Wang J; Wang LJ; Jin GH; Ying X; He CC; Guo XJ; Zhang JY; Zhang Y; Zhu Q
Tumour Biol; 2014 Jun; 35(6):6149-57. PubMed ID: 24652591
[TBL] [Abstract][Full Text] [Related]
8. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
10. Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.
Di Caro G; Carvello M; Pesce S; Erreni M; Marchesi F; Todoric J; Sacchi M; Montorsi M; Allavena P; Spinelli A
PLoS One; 2016; 11(2):e0148186. PubMed ID: 26859579
[TBL] [Abstract][Full Text] [Related]
11. CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma.
Wang Z; Xie H; Zhou L; Liu Z; Fu H; Zhu Y; Xu L; Xu J
Oncotarget; 2016 Aug; 7(32):51525-51534. PubMed ID: 27409666
[TBL] [Abstract][Full Text] [Related]
12. Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.
Yuan Z; Baker K; Redman MW; Wang L; Adams SV; Yu M; Dickinson B; Makar K; Ulrich N; Böhm J; Wurscher M; Westerhoff M; Medwell S; Moonka R; Sinanan M; Fichera A; Vickers K; Grady WM
Br J Cancer; 2017 Oct; 117(8):1202-1210. PubMed ID: 28809863
[TBL] [Abstract][Full Text] [Related]
13. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer.
Ng L; Wan TM; Lam CS; Chow AK; Wong SK; Man JH; Li HS; Cheng NS; Pak RC; Cheung AH; Yau TC; Lo OS; Foo DC; Poon JT; Poon RT; Pang RW; Law WL
PLoS One; 2015; 10(5):e0126219. PubMed ID: 25961724
[TBL] [Abstract][Full Text] [Related]
14. Thoracic recurrence in patients with curatively-resected colorectal cancer: incidence, risk factors, and value of chest CT as a postoperative surveillance tool.
Lee JH; Park CM; Joo I; Suh YJ; Hwang EJ; Kim H; Goo JM
Eur Radiol; 2019 Aug; 29(8):4303-4314. PubMed ID: 30350166
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of serum miR-103 predicts unfavorable prognosis in patients with colorectal cancer.
Wang DS; Zhong B; Zhang MS; Gao Y
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4518-4523. PubMed ID: 30058684
[TBL] [Abstract][Full Text] [Related]
16. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
17. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
[TBL] [Abstract][Full Text] [Related]
18. The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis.
Wang R; Zhao A; Cao N; Li Z; Zhang G; Liu F
Int J Colorectal Dis; 2020 Aug; 35(8):1463-1475. PubMed ID: 32572601
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum chemokine (C-C motif) ligand 2 levels and prognosis in colorectal cancer.
Szczepanik AM; Siedlar M; Szura M; Kibil W; Brzuszkiewicz K; Brandt P; Kulig J
Pol Arch Med Wewn; 2015; 125(6):443-51. PubMed ID: 26020569
[TBL] [Abstract][Full Text] [Related]
20. Clinically Applicable Serum Biomarkers Among 14 Candidates Associated With Recurrence of Stage II and III Colorectal Cancer.
Kim CW; Ha YJ; Tak KH; Roh SA; Kim SK; Kim SY; Kim YS; Cho DH; Kim JC
Anticancer Res; 2021 Sep; 41(9):4651-4658. PubMed ID: 34475094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
